Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Taysha Gene Therapies priced an underwritten public offering of 32.5 million shares at $6.00 per share and pre-funded warrants, expected to raise approximately $200 million in gross proceeds. The offering is expected to close on June 26, 2026. The company is a clinical-stage biotech focused on AAV-based gene therapies for CNS diseases, with its lead program TSHA-102 in development for Rett syndrome.